Digital Drug Regulation: CDSCO to Introduce Integrated Compliance Platform in 18 Months
New Delhi: In a major step towards modernising India's pharmaceutical regulatory ecosystem, the Central Drugs Standard Control Organisation (CDSCO) has announced plans to launch the first phase of a comprehensive end-to-end digital drug regulatory platform within the next 18 months.
Designed as a single-window interface for the pharmaceutical industry, the platform aims to streamline regulatory processes, enhance transparency, improve efficiency, and simplify compliance, marking a significant milestone in the country's ongoing regulatory reforms.
The announcement was made during the Global Drug Regulatory Conclave (GDRC) 2026, organised by Pharmexcil, which focused on strengthening India's pharmaceutical regulatory framework while preparing it for future healthcare challenges.
Addressing the inaugural session virtually on 30 July in New Delhi, Union Minister for Health and Family Welfare J.P. Nadda said that India is developing a modern, future-ready regulatory system that supports healthcare innovation without compromising patient safety, quality, or efficacy, BioSpectrum India reported.
He stated that the Central Drugs Standard Control Organisation (CDSCO) is undergoing extensive reforms driven by transparency, scientific excellence, operational efficiency, accountability, and digital governance. According to the Minister, initiatives such as digital regulatory platforms, risk-based regulatory oversight, strengthened inspection mechanisms, and enhanced surveillance systems are transforming India's drug regulatory ecosystem and enhancing global confidence in India's pharmaceutical sector.
Nadda also stressed the importance of greater international collaboration, urging regulatory authorities worldwide to strengthen information sharing, collaborate on regulatory science, undertake joint inspections, and work towards harmonised scientific standards to improve global access to safe, effective, and affordable medicines.
Supporting this vision, Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India (DCGI), announced that CDSCO will roll out the first phase of the end-to-end digital drug regulatory platform within the next 18 months, marking a major milestone in the digital transformation of India's pharmaceutical regulatory system.
During his keynote address, Dr Raghuvanshi outlined CDSCO's strategic roadmap, centred on digitalisation, innovation, quality assurance, and greater alignment with global regulatory practices. He noted that more than 99% of CDSCO's regulatory processes have already been digitised, resulting in improved transparency and significantly faster approval timelines.
Building on these advancements, CDSCO has also begun piloting the use of Artificial Intelligence (AI) across several regulatory functions to create a faster, more efficient, and data-driven regulatory ecosystem.
Highlighting the move towards digital authentication, the DCGI said, “Certificates of Pharmaceutical Product (CoPP) and cGMP certificates have now started being issued with QR codes to enable authentication and help exporters save up to six months” that exporters earlier spent securing the necessary clearances for product registration in overseas markets, ET reported.
Highlighting measures to improve quality and promote innovation, he said CDSCO has implemented a fully digitised Export No Objection Certificate (NOC) system, adopted globally aligned regulatory reliance pathways, and introduced accelerated approval mechanisms to provide patients with quicker access to innovative therapies.
He also revealed that regulatory authorities are currently considering waiving clinical trial requirements for approximately 25–30% of eligible innovative products, depending on their regulatory eligibility.
Emphasising support for innovation, Dr Raghuvanshi said the MedTech Mitra initiative has already assisted more than 800 startups in navigating regulatory requirements, adding that similar facilitation programmes are being planned for biologics and other emerging healthcare technologies.
Organised by the Pharmaceuticals Export Promotion Council of India (Pharmexcil) in association with the Central Drugs Standard Control Organisation (CDSCO), the Global Drug Regulatory Conclave (GDRC) 2026 brought together regulatory authorities from more than 40 countries, including the US, the UK, and Japan.
The event also focused on expanding the global acceptance of the Indian Pharmacopoeia (IP) to enable Indian pharmaceutical manufacturers to access new international markets while reducing regulatory compliance costs.
Speaking at the conclave, Pharmexcil Chairman Namit Joshi told ET, "As global expectations on quality and compliance continue to evolve, GDRC will help translate policy into consistent compliance across the industry, strengthening confidence in Indian pharmaceuticals across global markets".
